Pulmonx Reports Third Quarter 2026 Revenue and Operational Improvements

REDWOOD CITY, Calif., Oct. 27, 2026 /CourierPR/ -- Pulmonx Corporation, a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), reported financial results for the third quarter of 2026, which ended on September 30, 2026. The company achieved worldwide revenue of $22.8 million, marking a 6% increase from $21.5 million in the same period last year, both on a GAAP and constant currency basis.

In the United States, Pulmonx delivered $14.9 million in revenue, a 7% year-over-year increase. Internationally, the company reported $7.9 million in revenue, a 5% increase compared to the third quarter of 2025. Excluding China, international revenue grew by 9% on both a GAAP and constant currency basis. The gross margin for the quarter was 76%, up from 75% in the same period of 2025.

Operating expenses for the third quarter of 2026 were $24.9 million, a 18% decrease from $30.4 million in the third quarter of 2025. This reduction in expenses contributed to a net loss of $8.4 million, or $0.19 per share, compared to a net loss of $14.0 million, or $0.34 per share, in the same period of 2025. The company also reported an Adjusted EBITDA loss of $3.5 million, a reduction of 57% from an adjusted EBITDA loss of $8.2 million in the third quarter of 2025.

As of September 30, 2026, Pulmonx had $52.7 million in cash and cash equivalents. For the full year 2026, the company expects revenue to be in the range of $90 million to $92 million. Pulmonx also expects gross margin for the full year to be approximately 77%. The company anticipates total operating expenses for the full year 2026 to fall within the range of $108 million to $109 million, inclusive of approximately $14 million of non-cash stock-based compensation.

Pulmonx Corporation, a global leader in minimally invasive treatments for COPD, continues to focus on its core products, including the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports. These products are designed to assess and treat patients with severe emphysema/COPD who, despite medical management, are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a "breakthrough device." The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines, and is widely considered a standard of care treatment option for improving breathing, activity, and quality of life in patients with severe emphysema.

For the full year 2026, Pulmonx expects to maintain its focus on revenue growth and operational efficiency. The company is optimistic about its ability to continue advancing its strategic priorities and deliver on its financial outlook.